Evidence map›Paper›PMID 24561061›Full record

ReviewCancer letters2014

MicroRNAs in pancreatic malignancy: progress and promises.

Sanjeev K Srivastava, Sumit Arora, Seema Singh, Arun Bhardwaj, Courey Averett, Ajay P Singh

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancer letters, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. microRNA-21 Regulates Stemness in Pancreatic Ductal Adenocarcinoma Cells.International journal of molecular sciences · 2022
    Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. microRNA-3129 promotes cell proliferation in gastric cancer cell line SGC7901 via positive regulation of pRb.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2018
    Article
  18. Pancreatic cancer: Current status and Challenges.Current pharmacology reports · 2017
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Sanjeev K SrivastavaMitchell Cancer Institute, University of South Alabama, Mobile, AL, USA.
Sumit AroraMitchell Cancer Institute, University of South Alabama, Mobile, AL, USA.
Seema SinghMitchell Cancer Institute, University of South Alabama, Mobile, AL, USA.
Arun BhardwajMitchell Cancer Institute, University of South Alabama, Mobile, AL, USA.
Courey AverettMitchell Cancer Institute, University of South Alabama, Mobile, AL, USA.
Ajay P SinghMitchell Cancer Institute, University of South Alabama, Mobile, AL, USA; Department of Biochemistry and Molecular Biology, University of South Alabama, Mobile, AL, USA. Electronic address: asingh@health.southalabama.edu.

Funding

Targeting tumor-stromal interaction for pancreatic cancer therapyR01CA175772 · NCI · UNIVERSITY OF SOUTH ALABAMA · PI SINGH, AJAY PRATAP · 2014 to 2018
$1.9M
Myb, a key driver of pancreatic cancer progression and metastasisR21CA167137 · NCI · UNIVERSITY OF SOUTH ALABAMA · PI SINGH, AJAY PRATAP · 2012 to 2013
$346k
MicroRNAs in Pancreatic CancerR03CA137513 · NCI · UNIVERSITY OF SOUTH ALABAMA · PI SINGH, AJAY PRATAP · 2009 to 2010
$148k
ETV4 in pancreatic cancerR03CA169829 · NCI · UNIVERSITY OF SOUTH ALABAMA · PI SINGH, SEEMA · 2012 to 2013
$144k
NCI NIH HHS CA137513NCI NIH HHS CA167137NCI NIH HHS CA169829NCI NIH HHS CA175772NCI NIH HHS R01 CA175772NCI NIH HHS R03 CA137513NCI NIH HHS R03 CA169829NCI NIH HHS R21 CA167137
6 · The paper itself

Abstract

Despite progress in recent years, pancreatic cancer still remains a major clinical challenge. Its incidence and mortality rates have been on consistent rise underscoring the critical need for novel diagnostic, prognostic and therapeutic tools for its effective management. Recent studies have demonstrated that microRNAs (miRNAs/miRs) are deregulated in a variety of malignancies, including pancreatic cancer, and play a significant role in the initiation, progression and metastasis. Furthermore, their vital involvement in the therapeutic resistance of cancer has also been established. Hence, there has been enormous interest worldwide in investigating the roles of miRNAs in pancreatic cancer pathogenesis and exploiting their utility for clinical benefit. In this review, we summarize current knowledge on the role of miRNAs in pancreatic cancer and discuss their potential use as diagnostic and prognostic biomarkers, and as novel targets for development of effective therapeutic strategies.

Indexed as

Disease ProgressionHumansMicroRNAsNeoplasm MetastasisPancreatic NeoplasmsMicroRNAsDiagnosisDrug resistanceMetastasisMicroRNAsPancreatic cancerPrognosis and therapy

Identifiers

PMID24561061
PMCPMC3989403

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.